-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BofA Securities Downgrades Fate Therapeutics to Underperform From Buy, Adjusts Price Target to $4 From $72

BofA Securities Downgrades Fate Therapeutics to Underperform From Buy, Adjusts Price Target to $4 From $72

MT Newswires · 01/06/2023 05:09